Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Development fund awardee Gareth Bond is investigating how different types of genetic mutations cooperate to influence cancer risk, progression and response to therapy

A molecule of DNA with a radiating light representing mutation © Pixabay

There are two types of genetic variation that affect cancer. So-called somatic variation results from changes (mutations) in a person’s DNA that are acquired during their lifetime in individual parts of the body. These mutations only occur in some cells in the body and are often the result of damage with age or by carcinogens such as sunlight, smoking and some infections. By contrast, germline variation is inherited and so occurs in every cell in the body since birth. An example of germline variation is inheriting a mutation in the BRCA1 gene, which is associated with increased risk of breast cancer in families with these mutations.

Many research studies have investigated the separate effects of somatic and germline variation on cancer risk, progression and response to therapy. However, these studies generate an incomplete picture. For example, designing bespoke therapies to target cancer cells containing specific somatic mutations has had variable success, perhaps in part due to differing underlying germline variation between individuals. To make further progress, we need to learn more about whether germline and somatic variants interact to affect cancer. This is the question that Dr Ping Zhang asked as a post-doc in Dr Gareth Bond’s lab when it was at the Oxford Branch of the Ludwig Institute for Cancer Research.

In this paper published recently in the journal Cancer Research, the Ludwig Oxford researchers worked with colleagues at several other institutions to investigate the interplay between germline and somatic variants affecting the activity of the p53 tumour suppressor protein. p53 is a key protector against the development of cancers and somatic mutations in the gene coding for p53 are found in over half of all human cancers. Perturbation of p53 activity also influences cancer progression and drug response.

In this study, the team discovered evidence that germline cancer-risk p53 pathway mutations cooperate with somatic p53 gene mutations to alter cancer risk, progression and response to therapy, and can be used to identify novel, more effective therapies. With this increased understanding, this work has the potential to guide further discovery of future anti-cancer drug targets and novel combination therapies for enhancing precision medicine.

This work was funded by the CRUK Oxford Centre Development Fund.

Similar Stories

Early detection innovation award for Oxford researchers

Professor Julia Hippisley-Cox and Dr Tingting Zhu win funding for their collaborative project on novel test technologies for patient triage in primary care.

Dairy products linked to increased risk of cancer

The first major study to investigate dairy consumption and cancer risk in Chinese adults found that greater intake was associated with higher risks of liver cancer and female breast cancer.

Genetic testing could reduce adverse effects and hospital costs of a widely used chemotherapy

Testing for DPYD gene variants could be used to mitigate the side-effects of fluoropyrimidine-based chemotherapy